Literature DB >> 6656174

Elimination kinetics of plasma exchange.

F Keller, K Wagner, U Faber, J Scholle, H H Neumayer, M Maiga, G Schultze, G Offermann, M Molzahn.   

Abstract

Interest in the therapeutic use of plasma exchange for various diseases is growing. The two different effects of plasma exchange are elimination and activation. The kinetics are linear for elimination by plasma exchange, but not for activation. Plasma exchange is performed intermittently and can be described by intermittent kinetics. According to intermittent kinetics, plasma exchange removes 50% to 75% of a substance in plasma within 1-2 h, corresponding to an elimination half-life of 30-40 min. Hybrid kinetics, a mixture of actually intermittent but theoretically continuous elimination by plasma exchange, can however also be applied. Hybrid kinetics are more convenient and more reliable than intermittent kinetics. This is because hybrid kinetics are based solely on the concentrations before each plasma exchange; hybrid kinetics also reflect removal from the entire body and not just from the plasma compartment. According to hybrid kinetics, the amount of a substance in the body removed within 3-4 days is 50% of the difference between the initial and the final plasma concentration, depending on the intensity of plasma exchange. The intensity may well contribute at least in part to the beneficial effect of plasma exchange in various diseases.

Mesh:

Substances:

Year:  1983        PMID: 6656174     DOI: 10.1007/BF01530838

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  18 in total

1.  Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.

Authors:  P C Dau; J M Lindstrom; C K Cassel; E H Denys; E E Shev; L E Spitler
Journal:  N Engl J Med       Date:  1977-11-24       Impact factor: 91.245

2.  Control of dialysis by a single-pool urea model: the National Cooperative Dialysis Study.

Authors:  J A Sargent
Journal:  Kidney Int Suppl       Date:  1983-04       Impact factor: 10.545

3.  Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture's syndrome.

Authors:  J P Johnson; W Whitman; W A Briggs; C B Wilson
Journal:  Am J Med       Date:  1978-02       Impact factor: 4.965

4.  [Plasma separation with membranes--examinations in man (author's transl)].

Authors:  H G Sieberth; W Glöckner; H H Hirsch; H Borberg; G Dotzauer; P Mathieu
Journal:  Klin Wochenschr       Date:  1980-06-02

5.  Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture's syndrome.

Authors:  S B Erickson; S B Kurtz; J V Donadio; K E Holley; C B Wilson; A A Pineda
Journal:  Mayo Clin Proc       Date:  1979-11       Impact factor: 7.616

Review 6.  Clinical pharmacokinetics of digoxin.

Authors:  E Iisalo
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

7.  Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome.

Authors:  C M Lockwood; A J Rees; T A Pearson; D J Evans; D K Peters; C B Wilson
Journal:  Lancet       Date:  1976-04-03       Impact factor: 79.321

8.  Clinical trial of plasma exchange with a membrane filter in treatment of crescentic glomerulonephritis.

Authors:  H Asaba; S Rekola; A Bergstrand; H Wasserman; J Bergström
Journal:  Clin Nephrol       Date:  1980-08       Impact factor: 0.975

9.  Anti-acetylcholine receptor antibody titres in the sera of myasthenia patients treated with plasma exchange combined with immunosuppressive therapy.

Authors:  B Carter; R Harrison; G G Lunt; P O Behan; J A Simpson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-05       Impact factor: 10.154

10.  Remission of myasthenia gravis following plasma-exchange.

Authors:  A J Pinching; D K Peters
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

View more
  2 in total

Review 1.  Drug Dosing in Patients Undergoing Therapeutic Plasma Exchange.

Authors:  Sherif Hanafy Mahmoud; Jessica Buhler; Eric Chu; Suzie A Chen; Theresa Human
Journal:  Neurocrit Care       Date:  2021-02       Impact factor: 3.210

2.  Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates.

Authors:  David Salas; Karin L Kwikkers; Nerea Zabaleta; Andrea Bazo; Harald Petry; Sander J van Deventer; Gloria Gonzalez Aseguinolaza; Valerie Ferreira
Journal:  Blood Adv       Date:  2019-09-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.